PO.MCB09.04 · 分子与细胞生物学

线粒体蛋白酶YME1L通过STING途径调控AML中的1型干扰素信号传导

The mitochondrial protease YME1L regulates type 1 interferon signaling via the STING pathway in AML

海报缩略图:线粒体蛋白酶YME1L通过STING途径调控AML中的1型干扰素信号传导
编号 3273 展板 5 时间 4/20 02:00–05:00 区域 Section 23 主讲 Yihe Zhang, BS
分会场 Metabolic Studies in Brain, Pediatric, and Hematologic Cancers
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Yihe Zhang, Geethu Thomas, Rose Hurren, Yongran Yan, Marcela Gronda, Dakai Ling, Andrea Arruda, Mark David Minden, Aaron D. Schimmer

UHN Princess Margaret Cancer Centre, Toronto, ON, Canada

摘要 Abstract

中文摘要
酵母线粒体逃逸1样1(YME1L)是四种线粒体ATP依赖性蛋白酶之一,负责维持线粒体蛋白质稳态,并且是唯一作用于膜间隙底物的ATP依赖性蛋白酶。在此,我们研究了YME1L在急性髓系白血病(AML)中的表达和功能重要性。 与正常造血干细胞相比,YME1L蛋白在7个AML细胞系中的6个以及23例原代AML患者样本中的17例中上调。这种过表达在AML的各细胞遗传学风险组中均等发生。此外,高YME1L mRNA表达与AML患者较差的5年总生存率相关。 为评估YME1L在AML中的必需性,我们用shRNA在AML细胞系(OCI-AML2、NB4、TEX和THP-1)中敲低了该蛋白酶。YME1L敲低降低了所有受试细胞系的细胞增殖和克隆形成生长。有趣的是,通过Annexin V/PI染色测量,YME1L敲低并未诱导细胞死亡。相反,YME1L敲低诱导了AML分化,其证据是单核细胞分化标志物CD14的表达增加。 用shRNA耗竭YME1L也减少了TEX细胞和原代AML细胞在NSG免疫缺陷小鼠骨髓中的植入。 为研究YME1L耗竭的功能重要性,我们对YME1L耗竭后的AML细胞进行了RNA测序。YME1L敲低上调了与I型干扰素(IFN)信号传导、抗病毒防御反应和病毒模拟相关的基因。我们通过实时PCR和ELISA验证了结果,证实YME1L敲低后IFN-beta、IFN-gamma、ISG15、IFI44和IFIT2的上调。我们证明IFN信号的激活继发于cGAS-STING途径的激活,因为对STING的药理学抑制消除了YME1L耗竭后IFN信号的上调。cGAS-STING信号传导可由胞质中双链DNA(dsDNA)的积累激活。我们显示YME1L敲低促进了dsDNA从线粒体泄漏到胞质中。我们还证明dsDNA是通过线粒体VDAC通道泄漏到胞质中的,因为用VDAC通道抑制剂VBIT-4处理AML细胞可防止YME1L敲低后胞质dsDNA的积累和IFN信号的上调。 总之,我们证明YME1L在一部分AML细胞系和原代患者样本中过表达,并且是AML增殖和克隆形成生长所必需的。YME1L调控mtDNA向胞质的泄漏、cGAS-STING-IFN轴的激活,并控制AML分化。因此,我们揭示了线粒体蛋白酶YME1L的新功能,并提示靶向YME1L可能是针对某些AML患者的一种新策略。
查看英文原文 English abstract
Yeast mitochondrial escape 1-like 1 (YME1L) is one of four mitochondrial ATP-dependent proteases responsible for maintaining mitochondrial proteostasis and is the sole ATP-dependent protease acting on substrates in the intermembrane space. Here, we investigated the expression and functional importance of YME1L in acute myeloid leukemia (AML). YME1L protein was upregulated in 6 out of 7 AML cell lines and 17 of 23 primary AML patient samples compared to normal hematopoietic stem cells. Overexpression occurred equally across cytogenetic risk groups of AML. Moreover, high YME1L mRNA expression correlated with inferior 5-year overall survival in AML patients. To evaluate the essentiality of YME1L in AML, we knocked down the protease in AML cell lines (OCI-AML2, NB4, TEX, and THP-1) with shRNA. YME1L knockdown decreased cell proliferation and clonogenic growth in all tested cell lines. Interestingly, YME1L knockdown did not induce cell death as measured by Annexin V/PI staining. Rather, YME1L knockdown induced AML differentiation as evidenced by increased expression of CD14, a marker of monocytic differentiation. Depletion of YME1L with shRNA also reduced the engraftment of TEX cells and primary AML cells in the marrow of NSG immunodeficient mice. To investigate the functional importance of YME1L depletion, we performed RNA sequencing of AML cells after YME1L depletion. Knockdown of YME1L upregulated genes associated with type I interferon (IFN) signaling, defense response to virus, and viral mimicry. We validated the results by real-time PCR and ELISA, confirming the upregulation of IFN-beta, IFN-gamma, ISG15, IFI44, and IFIT2 following YME1L knockdown. We demonstrated that activation of IFN signaling was secondary to activation of the cGAS-STING pathway as pharmacological inhibition of STING abolished the upregulation of IFN signaling after YME1L depletion. cGAS-STING signalling can be activated by the accumulation of double-stranded DNA (dsDNA) in the cytosol. We showed that YME1L knockdown promoted the leakage of dsDNA from the mitochondria into the cytosol. We also demonstrated that dsDNA leaked into the cytosol via the mitochondrial VDAC channel as treatment of AML cells with the VDAC channel inhibitor, VBIT-4, prevented the accumulation of cytosolic dsDNA and the upregulation of IFN signaling after YME1L knockdown in AML cells. In summary, we demonstrated that YME1L is overexpressed in a subset of AML cell lines and primary patient samples and is required for AML proliferation and clonogenic growth. YME1L regulates the leakage of mtDNA into the cytoplasm, activation of the cGAS-STING-IFN axis, and controls AML differentiation. Thus, we have uncovered novel functions for the mitochondrial protease YME1L and suggest that targeting YME1L may be a novel strategy in the case of some AML patients.
利益披露 Disclosure
Y. Zhang, None.. G. Thomas, None.. R. Hurren, None.. Y. Yan, None.. M. Gronda, None.. D. Ling, None.. A. Arruda, None.. M. D. Minden, None. A. D. Schimmer, Takeda Pharmaceuticals ), Other, consulting fees. BMS ). Medivir AB ). Novartis Other, Consulting fees. Jazz Other, Consulting fees. Otsuka Pharmaceuticals Other, Consulting fees.

← 返回 AACR 2026 检索